Aspen confirms release of COVID-19 vaccines to Johnson & Johnson for supply to South Africa
Aspen confirms release of COVID-19 vaccines to Johnson & Johnson for supply to South Africa ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number: 1985/002935/06 Share code: APN ISIN: ZAE000066692 LEI: 635400ZYSN1IRD5QWQ94 and its subsidiaries (collectively “Aspen” or “the Group”) ASPEN CONFIRMS RELEASE OF COVID-19 VACCINES TO JOHNSON & JOHNSON FOR SUPPLY TO SOUTH AFRICA Aspen is pleased to confirm that the first supplies to South Africa of the Johnson & Johnson COVID-19 vaccines, from the new API source located in Europe, will be released to Johnson & Johnson from its flagship Gqeberha-based manufacturing site later today. These vaccines will be further distributed throughout South Africa in line with the various distribution arrangements between Johnson & Johnson, the National Department of Health and other stakeholders. In addition, vaccines from these batches will be made available through the African Vaccine Acquisition Task Team/African Union platform. This represents a significant landmark for South Africa and Africa as these are the first COVID-19 vaccines to be produced on the African continent, by an African producer for South African and African patients. Supplies will also be made to the European Union and other offshore markets. Aspen’s ability to produce these vaccines on behalf of Johnson & Johnson builds on its strategic vision of delivering high quality, affordable medicines that improve health outcomes for patients in its home country, South Africa, Africa and around the world. Supply for Africa and South Africa represents a big step forward in ensuring that Africa can address its healthcare priorities. The manufacture of the Johnson & Johnson COVID-19 vaccine builds on the global contributions Aspen has already made in fighting the COVID-19 pandemic with both its anaesthetics portfolio and dexamethasone supply. The full press release can be viewed on the news page of the Aspen website: https://www.aspenpharma.com/group-news/ Durban 26 July 2021 Sponsor Investec Bank Limited Date: 26-07-2021 08:58:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.